[{"orgOrder":0,"company":"Rznomics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Rznomics \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"Rznomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Rznomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Inapplicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Rznomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Inapplicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Rznomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Sunesis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Merger","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Sunesis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Sunesis Pharmaceuticals"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Sunesis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Merger","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Sunesis Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Sunesis Pharmaceuticals"},{"orgOrder":0,"company":"Rznomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Rznomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Inapplicable"},{"orgOrder":0,"company":"Rznomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RZ-001","moa":"||hTERT expression","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rznomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rznomics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rznomics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Private Placement","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Preclinical","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GenVivo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GVO-1102","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"GenVivo","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenVivo \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GenVivo \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viracta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nanatinostat","moa":"||HDAC","graph1":"Oncology","graph2":"Phase II","graph3":"Viracta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Viracta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viracta Therapeutics \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Valcyte
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
